Further Information
MLANA, Antigen LB39-AA, Antigen SK29-AA, Melan-A, Protein Melan-A, MART-1, MART1
Flow Cytometry: 0.5-1 ug/million cells in 0.1ml
Immunofluorescence: 0.5-1 ug/ml
Immunohistochemistry (FFPE): 0.5-1 ug/ml for 30 min at RT (1)
Western blot: 0.5-1 ug/ml
Prediluted format : incubate for 30 min at RT (2)
Optimal dilution of the Melan-A antibody should be determined by the researcher.
1. Staining of formalin-fixed tissues is enhanced by boiling tissue sections in 10mM Citrate buffer, pH 6.0, for 10-20 min followed by cooling at RT for 20 minutes
2. The prediluted format is supplied in a dropper bottle and is optimized for use in IHC. After epitope retrieval step (if required), drip mAb solution onto the tissue section and incubate at RT for 30 min.
This antibody recognizes a protein doublet of 20-22kDa, identified as MART-1 (Melanoma Antigen Recognized by T cells 1) or Melan-A. MART-1 is a newly identified melanocyte differentiation antigen recognized by autologous cytotoxic T lymphocytes. Seven other melanoma associated antigens recognized by autologous cytotoxic T cells include MAGE-1, MAGE-3, tyrosinase, gp100, gp75, BAGE-1, and GAGE-1. Subcellular fractionation shows that MART-1 is present in melanosomes and endoplasmic reticulum. This mAb labels melanomas and other tumors showing melanocytic differentiation. It is also a useful positive-marker for angiomyolipomas. It does not stain tumor cells of epithelial, lymphoid, glial, or mesenchymal origin.
PBS with 0.1 mg/ml BSA and 0.05% sodium azide
0.2 mg/mL
Unconjugated
Optimal dilutions/concentrations should be determined by the end user. The information provided is a guideline for product use. This product is for research use only.
Recombinant human MLANA protein was used as the immunogen for the Melan-A antibody.
2315
melan-A
MLANA
Homo sapiens
Liquid
Protein G affinity chromatography
Immunology
Q16655
Optimal dilutions for each application to be determined by the researcher